Achaogen: Hurdles of antibiotic R&D on display in Achaogen's divergent study outcomes
A NEJM editorial highlighted the challenges still facing companies in antibiotic development, particularly in serious resistant infections.
Read full article »
Achaogen develops and commercializes novel antibacterials to treat the multi-drug resistant gram-negative infections.
Read more